Ambu A/S (CPH:AMBUB), a developer, producer and marketer of life-saving equipment, announced on Tuesday the receipt of US FDA clearance for disposable colonoscope in the US.
With this milestone, Ambu said it is cleared to address the over 15 million annual procedure market for colonoscopy in the US.
Currently, Ambu operates in the field of single-use endoscopy for pulmonary (visualisation of the airways) with aScope and has sold more than 700,000 aScopes since the launch in 2013.
Ambu provides professional diagnostic, life supporting and training equipment. Its products are used for respiratory support and cardiopulmonary resuscitation, immobilisation and protection against infections. The company sells to hospitals, rescuers, armed forces and industry.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib